Humacyte Raises $60M In Oversubscribed Registered Direct Offering With Institutional Investors; Company Has Agreed To Sell 28,436,018 Shares Of Its Common Stock And Warrants To Purchase 28,436,018 Shares Of Common Stock At A Combined Price Of $2.11

Author: Benzinga Newsdesk | October 07, 2025 09:05am

Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it entered into a securities purchase agreement with certain fundamental institutional investors to purchase approximately $60.0 million worth of its common stock and warrants in an oversubscribed registered direct offering.

Under the terms of the securities purchase agreement, the Company has agreed to sell 28,436,018 shares of its common stock and warrants to purchase 28,436,018 shares of common stock. The warrants will become exercisable 180 days following the date of issuance, have an exercise price of $2.11 per share, and will expire on April 7, 2031. The purchase price for one share of common stock and one warrant will be $2.11.

The gross proceeds to the Company from the registered direct offering are estimated to be approximately $60.0 million, before deducting the placement agent's fees and other estimated offering expenses. The offering is expected to close on or about October 8, 2025, subject to the satisfaction of customary closing conditions.

D. Boral Capital LLC is acting as exclusive placement agent for the offering.

Posted In: HUMA